SCHEMBL6844486

SCHEMBL6844486

O=S(=O)(Nc1ccc2c(ccn2-c2cccnc2)c1)c1ccc(F)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.47
GFER P55789 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.44
MEN1 O00255 2/20 0.44
PKM P14618 2/20 0.43
GLO1 Q04760 1/20 0.43
BRD1 O95696 4/20 0.42
BRPF1 P55201 4/20 0.42
BRD4 O60885 2/20 0.42
BRD9 Q9H8M2 2/20 0.42
ADRB2 P07550 1/20 0.42
ADRB1 P08588 1/20 0.42
ADRB3 P13945 1/20 0.42
BRPF3 Q9ULD4 1/20 0.42
CCR9 P51686 1/20 0.41
SIRT6 Q8N6T7 1/20 0.41
HTR6 P50406 1/20 0.40
ALPL P05186 1/20 0.40
NAMPT P43490 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6656125 0.89 MEN1 (0.57) KMT2ASMN1; SMN2LMNAMEN1PKM
SCHEMBL6665282 0.88 LMNA (0.45) KMT2ASMN1; SMN2LMNAMEN1PKM
SCHEMBL6844273 0.86 BRD4 (0.57) KMT2ASMN1; SMN2LMNAMEN1PKM
SCHEMBL6840912 0.85 POLB (0.54) KMT2ASMN1; SMN2LMNAMEN1PKM
SCHEMBL6656751 0.84 ALPL (0.49) KMT2ALMNAMEN1ALPLNAMPT
SCHEMBL6845454 0.84 KMT2A (0.51) KMT2ASMN1; SMN2MEN1BRD1BRPF1
SCHEMBL6840520 0.84 ALPL (0.46) KMT2AGFERLMNAMEN1PKM
SCHEMBL6846145 0.82 ALDH1A1 (0.60) KMT2ASMN1; SMN2LMNAMEN1BRD1
SCHEMBL6658847 0.82 BRPF1 (0.60) GLO1BRD1BRPF1BRD4BRD9
SCHEMBL6844284 0.82 BRD1 (0.53) KMT2AMEN1PKMBRD1BRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236110-A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors CYP17A1, IDO1, CYP21A2 KMT2A 1387/4885GFER 1157/4885SMN1; SMN2 4413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.